Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Company Overview - The second quarter performance was good, slightly ahead of expectations for both revenue and profit [2] - The Life Science business has shown consistent stability despite pressures from pharmaceutical, biotech, and academic government customers over the past couple of years [2] Business Performance - There has been a continued low single-digit growth in consumables, which are indicative of underlying lab activity [2] - This marks the fifth consecutive quarter of sequential growth in consumables, indicating a positive trend [3] - However, the instrument segment experienced a decline in the mid- to high range [3]